MRUS - メルス (Merus N.V.)

MRUSのニュース

   Merus N.V.: Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update  2023/02/28 21:34:00 Finanz Nachrichten
- Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 - Petosemtamab clinical and regulatory update planned for first half of 2023 …
   Can you still get a good price for Merus N.V. (MRUS) Shares at this point?  2023/02/10 15:08:00 US Post News
In Thursday’s session, Merus N.V. (NASDAQ:MRUS) marked $18.03 per share, up from $16.02 in the previous session. While Merus N.V. has overperformed by 12.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRUS fell by -28.34%, with highs and lows ranging from $30.81 to $12.03, whereas […]
   Merus N.V. PT Lowered to $35 at Guggenheim  2023/01/03 12:42:15 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-receives-investment-bank-analyst-rating-update-432SI-2972255
   Merus: Market Pricing In Further Downside (NASDAQ:MRUS)  2022/12/25 13:45:41 Seeking Alpha
Merus traded with wide-reaching volatility over the past 2 years. Read more to see my thoughts on its Zenocutuzumab trial and why we''re on the sidelines for now.
   Merus N.V. PT Lowered to $46 at BMO Capital  2022/12/20 09:13:02 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-lowered-to-46-at-bmo-capital-432SI-2967652
   Do investors need to be concerned about Merus N.V. (MRUS)?  2022/11/24 14:48:00 US Post News
Merus N.V. (NASDAQ:MRUS) closed Wednesday at $15.53 per share, down from $15.94 a day earlier. While Merus N.V. has underperformed by -2.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRUS fell by -38.81%, with highs and lows ranging from $33.09 to $12.03, whereas the simple […]
   Can Merus N.V. (NASDAQ: MRUS) Still Be Considered A Loss When It’s Down -48.58% YTD?  2022/11/19 13:30:00 Marketing Sentinel
During the last session, Merus N.V. (NASDAQ:MRUS)’s traded shares were 0.89 million, with the beta value of the company hitting 0.92. At the end of the trading day, the stock’s price was $16.35, reflecting an intraday loss of -4.16% or -$0.71. The 52-week high for the MRUS share is $33.09, that puts it down -102.39 … Can Merus N.V. (NASDAQ: MRUS) Still Be Considered A Loss When It’s Down -48.58% YTD? Read More »
   Merus N.V. PT Lowered to $30 at Citi  2022/11/15 21:15:04 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-lowered-to-30-at-citi-432SI-2945083
   Merus N.V. (MRUS) can beat the pack with these strategies  2022/11/07 14:32:00 US Post News
Merus N.V. (NASDAQ:MRUS) marked $17.07 per share on Friday, up from a previous closing price of $15.28. While Merus N.V. has overperformed by 11.71%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MRUS fell by -45.62%, with highs and lows ranging from $33.09 to $12.03, whereas […]
   Merus N.V. (NASDAQ:MRUS) Is 16.18% Above Its 52-Week Low, But How Long Can It Continue?  2022/11/03 18:00:00 Marketing Sentinel
In recent trading session, Merus N.V. (NASDAQ:MRUS) saw 1.11 million shares changing hands at last check today with its beta currently measuring 0.93. Company’s recent per share price level of $16.07 trading at -$4.31 or -21.15% at last check today assigns it a market valuation of $926.27M. That most recent trading price of MRUS’s stock … Merus N.V. (NASDAQ:MRUS) Is 16.18% Above Its 52-Week Low, But How Long Can It Continue? Read More »
   Merus N.V. PT Raised to $39 at SVB Leerink  2022/10/12 17:41:01 Investing.com
https://www.investing.com/news/pro/merus-nv-pt-raised-to-39-at-svb-leerink-432SI-2910858
   Merus NV (MRUS) Investor Presentation- Slideshow (NASDAQ:MRUS)  2022/09/19 14:23:26 Seeking Alpha
The following slide deck was published by Merus N.V.
   Merus (MRUS) Investor Presentation - Slideshow (NASDAQ:MRUS)  2022/09/09 21:18:28 Seeking Alpha
The following slide deck was published by Merus N.V.
   Merus N.V.: Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics  2022/09/07 20:17:00 Finanz Nachrichten
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022(Nasdaq: MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispeci…
   MRUS stock gains as Stifel initiates with Buy on three bispecific antibodies (NASDAQ:MRUS)  2022/08/02 17:28:39 Seeking Alpha
The shares of Dutch biotech Merus N.V. (MRUS) added ~8% on Tuesday after Stifel initiated its coverage on the stock with a Buy recommendation as the analysts weighed in on the potential…

calendar